ANTIBODIES AGAINST METAL-CHELATES
ANTIBODIES AGAINST METAL-CHELATES
复制标题
DOI：
10.1038/316265a0
复制
发表时间：
1985-01-01
期刊：
影响因子：
64.8
通讯作者：
FRINCKE, JM
中科院分区：
文献类型：
--
作者：
REARDAN, DT;MEARES, CF;FRINCKE, JM
由于单克隆抗体可以识别并结合特定的原子团，如肿瘤抗原，它们有望在体内用作放射性核素、药物或其他附加分子的载体，用于疾病的诊断和治疗1 -3。通过双功能螯合剂将金属离子连接到抗体上，可以将金属元素的不同核、物理和化学性质添加到这些特异性结合蛋白上（参考文献4和其中的参考文献）。最终目的是将探针结合特性工程化到抗体本身中，我们现在已经制备了针对铟的EDTA螯合物的单克隆抗体。这些抗体显示出对铟螯合物的显著偏好;改变为另一种金属如钪或镓可以使抗体结合常数降低三个数量级以上。这些抗体还对螯合放射性核素的生物分布引入了新的控制程度，显著改变了它们在肿瘤和正常器官中的摄取。
Because monoclonal antibodies can recognize and bind to specific groups of atoms such as tumour antigens, they have promise for usein vivoas carriers of radionuclides, drugs or other appended molecules for diagnosis and treatment of disease1–3. Attachment of metal ions to antibodies by means of bifunctional chelating agents can add the diverse nuclear, physical and chemical properties of the metallic elements to these specific binding proteins (ref. 4 and refs therein). With the ultimate aim of engineering probe-binding properties into the antibodies themselves, we have now prepared monoclonal antibodies against the EDTA chelate of indium. These antibodies show a remarkable preference for indium chelates; changing to another metal such as scandium or gallium can decrease the antibody-binding constant by more than three orders of magnitude. These antibodies also introduce a new degree of control over the biological distributions of chelated radionuclides, markedly altering their uptake in tumours and normal organs.